Skip to main content
SpringerLink
Log in

Neisseria meningitidis Vaccines

  • Chapter
New Bacterial Vaccines

Part of the book series: Medical Intelligence Unit ((MIUN))

  • 174 Accesses

Summary

Meningococcal disease, both endemic and epidemic, remains a major cause of meningitis in many countries. Protective immunity is mediated primarily by bactericidal antibodies against the capsular polysaccharides as well as against outer membrane protein and lipopolysaccharide components. This article focuses on the new conjugate vaccines for serogroups A, C, Y and W135 as well as the latest approaches to development of group B vaccines. Group C meningococcal polysaccharide-protein conjugate vaccines have been used in the United Kingdom since November 1999 and are over 90% effective in both infants and children. Outer membrane protein vaccines have shown good efficacy against group B in individuals over 4 years of age, but most group B disease occurs in younger children. Newer group B vaccines are under development using new immunization regimens, individual outer membrane proteins and lipopolysaccharide conjugates. The problem of a universally effective group B vaccine may require new avenues of research.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Frasch CE. Meningococcal vaccines: Past, present and future. In: Cartwright K, ed. Meningococcal Disease. New York: Wiley, 1995:245–83.

    Google Scholar 

  2. Peltola H. Meningococcal vaccines — Current status and future possibilities. Drugs 1998; 55:347–66.

    Article  PubMed  CAS  Google Scholar 

  3. Zollinger WD. New and improved vaccines against meningococcal disease. In: Levine MM, Woodrow GC, Kaper JB, eds. New Generation Vaccines. 2nd ed. New York: Marcel Dekker, 1997:469–88.

    Google Scholar 

  4. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969; 129:1327–48.

    Article  PubMed  CAS  Google Scholar 

  5. Granoff DM, Holmes SJ, Osterholm MT et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis 1993; 168:663–71.

    Article  PubMed  CAS  Google Scholar 

  6. Richmond P, Borrow R, Miller E et al. Meningococcal serogroup C conjugate vaccine is immunogenic in infancy and primes for memory. J Infect Dis 1999; 179:1569–72.

    Article  PubMed  CAS  Google Scholar 

  7. Booy R, Kroll JS. Is Haemophilus influenzae finished? J Antimicrob Chemother 1997; 40:149–53.

    Article  PubMed  CAS  Google Scholar 

  8. Roberts RB. The relationship between group A and group C meningococcal polysaccharides and serum opsonins in man. J Exp Med 1970; 131:499–513.

    Article  PubMed  CAS  Google Scholar 

  9. Sim RJ, Harrison MM, Moxon ER et al. Underestimation of meningococci in tonsillar tissue by nasopharyngeal swabbing. Lancet 2000; 356:1653–4.

    Article  PubMed  CAS  Google Scholar 

  10. Swartley JS, Marfin AA, Edupuganti S et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997; 94:271–6.

    Article  PubMed  CAS  Google Scholar 

  11. Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N Engl J Med 2000; 342:219–20.

    Article  PubMed  CAS  Google Scholar 

  12. Lennon D, Gellin B, Hood D et al. Successful intervention in a Group A meningococcal outbreak in Auckland, New Zealand. Pediatr Infect Dis J 1992; 11:617–23.

    PubMed  CAS  Google Scholar 

  13. Käyhty H, Peltola H, Eskola J et al. Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age. Pediatrics 1989; 84:995–9.

    Google Scholar 

  14. Maslanka SE, Tappero JW, Plikaytis BD et al. Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine. Infect Immun 1998; 66:2453–9.

    PubMed  CAS  Google Scholar 

  15. De Wals P, De Serres G, Niyonsenga T. Effectiveness of a mass immunization campaign against serogroup C meningococcal disease in Quebec. J Amer Med Assoc 2001; 285:177–81.

    Article  Google Scholar 

  16. Pon RA, Lussier M, Yang QL et al. N-propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J Exper Med 1997; 185:1929–38.

    Article  CAS  Google Scholar 

  17. Granoff DM, Gupta RK, Belshe RB et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis 1998; 178:870–4.

    Article  PubMed  CAS  Google Scholar 

  18. MacDonald NE, Halperin SA, Law BJ et al. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers — A randomized controlled trial. J Amer Med Assoc 1998; 280:1685–9.

    Article  CAS  Google Scholar 

  19. Richmond P, Kaczmarski E, Borrow R et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis 2000; 181:761–4.

    Article  PubMed  CAS  Google Scholar 

  20. Schneerson R, Barrera O, Sutton A et al. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates. J Exp Med 1980; 152:361–76.

    Article  PubMed  CAS  Google Scholar 

  21. Bisgard KM, Kao A, Leake J et al. Haemophilus influenzae invasive disease in the United States, 1994–1995: Near dissappearance of a vaccine-preventable childhood disease. Emerging Infect Dis 1998; 4:1–14.

    Article  Google Scholar 

  22. Beuvery EC, Rossum FV, Nagel J. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect Immun 1982; 37:15–22.

    PubMed  CAS  Google Scholar 

  23. Beuvery EC, Miedema F, Delft RV et al. Preparation and Immunochemical characterization of meningococcal group C polysaccharide-tetanus toxoid conjugates as a new generation of vaccines. Infect Immun 1983; 40:39–45.

    PubMed  CAS  Google Scholar 

  24. Beuvery EC, Miedema F, Delft RV et al. Vaccine potential of meningococcal group C polysaccharide-tetanus toxoid conjugate. J Infect 1983; 6:247–55.

    Article  PubMed  CAS  Google Scholar 

  25. Jennings HJ, Lugowski C. Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates. J Immunol 1981; 127:1011–8.

    Google Scholar 

  26. Beuvery EC, Roy R, Kanhai V et al. Characteristics of two types of meningococcal group C polysaccharide conjugates using tetanus toxoid as protein carrier protein. Dev Biol Stand 1986; 65:197–204.

    PubMed  CAS  Google Scholar 

  27. Beuvery EC, Delft RV, Miedema F et al. Immunological evaluation of meningococcal group C polysaccharide-tetanus toxoid conjugate in mice. Infect Immun 1983; 41:609–17.

    PubMed  CAS  Google Scholar 

  28. Costantino P, Viti S, Podda A et al. Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C. Vaccine 1992; 10:691–8.

    Article  PubMed  CAS  Google Scholar 

  29. Anderson EL, Bowers T, Mink CM et al. Safety and immunogenicity of meningococcal A and C polysaccharide conjugate vaccine in adults. Infect Immun 1994; 62:3391–5.

    PubMed  CAS  Google Scholar 

  30. Lieberman JM, Chiu SS, Wong VK et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitides oligosaccharide-protein conjugate vaccine in young children — A randomized controlled trial. J Amer Med Assoc 1996; 275:1499–503.

    Article  CAS  Google Scholar 

  31. Twumasi Jr PA, Kumah S, Leach A et al. A trial of a group A plus group C meningococcal polysaccharide- protein conjugate vaccine in African infants. J Infect Dis 1995; 171:632–8.

    Article  PubMed  Google Scholar 

  32. Granoff DM, Maslanka SE, Carlone GM et al. A modified enzyme-linked immunosorbent assay for measurement of antibody responses to meningococcal C polysaccharide that correlate with bactericidal responses. Clin Diagn Lab Immunol 1998; 5:479–85.

    PubMed  CAS  Google Scholar 

  33. Granoff DM, Forrest B, Rappuoli R. Meningococcal polysaccharide-protein conjugate vaccines. Int J Infect Dis 1997; 1:152–7.

    Article  Google Scholar 

  34. Miller E, Salisbury D, Ramsey M. Planning, registration, and implementation of an immunization campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20:S58–67.

    Article  PubMed  Google Scholar 

  35. Feavers IM. Meningococcal vaccines and vaccine development. In: Pollard AJ, Maidan MCJ, eds. Meningococcal Vaccines: Methods and Protocols. New York: Humana Press, 2001:1–22.

    Chapter  Google Scholar 

  36. Borrow R, Andrews N, Goldblatt D et al. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection. Infect Immun 2001; 69:1568–73.

    Article  PubMed  CAS  Google Scholar 

  37. MacLennan JM, Shackley F, Heath PT et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants — A randomized controlled trial. J Amer Med Assoc 2000; 283:2795–801.

    Article  CAS  Google Scholar 

  38. Bramley JC, Hall T, Finn A et al. Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age. Vaccine 2001; 19:2924–31.

    CAS  Google Scholar 

  39. Richmond P, Borrow R, Goldblatt D et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J Infect Dis 2001; 183:160–3.

    Article  PubMed  CAS  Google Scholar 

  40. Choo S, Zuckerman J, Goilav C et al. Immunogenicity and reactogenicity of a group C meningococcal conjugate vaccine compared with a group A + C meningococcal polysaccharide vaccine in adolescents in a randomised observer-blind controlled trial. Vaccine 2000; 18:2686–92.

    Article  PubMed  CAS  Google Scholar 

  41. Richmond P, Borrow R, Findlow J et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: Reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect Immun 2001; 69:2378–82.

    Article  PubMed  CAS  Google Scholar 

  42. Borrow R, Longworth E, Gray SJ et al. Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom. FEMS Immunol Med Microbiol 2000; 28:189–91.

    Article  PubMed  CAS  Google Scholar 

  43. Lewis R, Nathan N, Diarra L et al. Timely detection of meningococcal meningitis epidemics in Africa. Lancet 2001; 358:287–93.

    Article  PubMed  CAS  Google Scholar 

  44. Robbins JB, Schneerson R, Gotschlich EC. A rebuttal: epidemic and endemic meningococcal, meningitis in sub-Saharan Africa can be prevented now by routine immunization with group A meningococcal capsular polysaccharide vaccine. Pediatr Infect Dis J 2000; 19:945–53.

    Article  PubMed  CAS  Google Scholar 

  45. Robbins JB, Towne DW, Gotschlich EC et al. “Love’s labours lost”: failure to implement mass vaccination against group A meningococcal meningitis in sub-Saharan Africa. Lancet 1997; 350:880–2.

    Article  PubMed  CAS  Google Scholar 

  46. Campagne G, Garba A, Fabre P et al. Safety and immunogenicity of three doses of a Neisseria meningitidis A+C diphtheria conjugate vaccine in infants from Niger. Pediatr Infect Dis J 2000; 19:144–50.

    Article  PubMed  CAS  Google Scholar 

  47. Sierra GVG, Campa HC, Varcacel NM et al. Vaccine against group B Neisseria meningitidis: Protection trial and mass vaccination results in Cuba. NIPH Ann 1991; 14:195–210.

    PubMed  CAS  Google Scholar 

  48. Bjune G, Hoiby EA, Gronnesby JK et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991; 338:1093–6.

    Article  PubMed  CAS  Google Scholar 

  49. Boslego J, Garcia J, Cruz C et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 1995; 13:821–30.

    Article  PubMed  CAS  Google Scholar 

  50. Noronha CP, Struchiner CJ, Halloran ME. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: A case-control study. Int J Epidemiol 1995; 24:1050–7.

    Article  PubMed  CAS  Google Scholar 

  51. De Moraes JC, Perkins BA, Camargo MCC et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992; 340:1074–8.

    Article  PubMed  Google Scholar 

  52. Milagres LG, Ramos SR, Sacchi CT et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine: Comparison with efficacy. Infect Immun 1994; 62:4419–24.

    PubMed  CAS  Google Scholar 

  53. Perkins BA, Jonsdottir K, Briem H et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998; 177:683–91.

    Article  PubMed  CAS  Google Scholar 

  54. Milagres LG, Gorla MCO, Rebelo MC et al. Bactericidal antibody response to Neisseria meningitidis serogroup B in patients with bacterial meningitis: effect of immunization with an outer membrane protein vaccine. FEMS Immunol Med Microbiol 2000; 28:319–27.

    Article  PubMed  CAS  Google Scholar 

  55. Wedege E, Hoiby EA, Rosenqvist E et al. Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial. Infect Immun 1998; 66:3223–31.

    PubMed  CAS  Google Scholar 

  56. Rosenqvist E, Hoiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995; 63:4642–52.

    PubMed  CAS  Google Scholar 

  57. Tappero JW, Lagos R, Ballesteros AM et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines — A randomized controlled trial in Chile. Journal of the American Medical Association 1999; 281:1520–7.

    Article  PubMed  CAS  Google Scholar 

  58. Milagres LG, Gorla MCA, Sacchi CT et al. Specificity of bactericidal antibody response to serogroup B meningococcal strains in Brazilian children after immunization with an outer membrane vaccine. Infect Immun 1998; 66:4755–61.

    PubMed  CAS  Google Scholar 

  59. Haneberg B, Dalseg R, Wedege E et al. Intranasal administration of a meningococcal outer membrane vesicle vaccine induces persistent local mucosal antibodies and serum antibodies with strong bactericidal activity in humans. Infect Immun 1998; 66:1334–41.

    PubMed  CAS  Google Scholar 

  60. Drabick JJ, Brandt BL, Moran EE et al. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers. Vaccine 1999; 18:160–72.

    Article  PubMed  CAS  Google Scholar 

  61. Ala’Aldeen DAA, Borriello SP. The meningococcal transferrin-binding proteins 1 and 2 are both surface exposed and generate bactericidal antibodies capable of killing homologous and heterologous strains. Vaccine 1996; 14:49–53.

    Article  PubMed  Google Scholar 

  62. Gorringe AR, Borrow R, Fox AJ et al. Human antibody response to meningococcal transferrin binding proteins: Evidence for vaccine potential. Vaccine 1995; 13:1207–12.

    Article  PubMed  CAS  Google Scholar 

  63. Rosenqvist E, Hoiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995; 63:4642–52.

    PubMed  CAS  Google Scholar 

  64. Rokbi B, Mignon M, Maitre-Wilmotte G et al. Evaluation of recombinant transferrin-binding protein B variants from Neisseria meningitidis for their ability to induce cross-reactive and bactericidal antibodies against a genetically diverse collection of serogroup B strains. Infect Immun 1997; 65:55–63.

    PubMed  CAS  Google Scholar 

  65. West D, Reddin K, Matheson M et al. Recombinant Neisseria meningitidis transferrin binding protein A protects against experimental meningococcal infection. Infect Immun 2001; 69:1561–7.

    Article  PubMed  CAS  Google Scholar 

  66. Fukasawa LO, Gorla MCO, Schenkman RPF et al. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate. Vaccine 1999; 17:2951–8.

    Article  PubMed  CAS  Google Scholar 

  67. Ward SJ, Scopes D, Christodoulides M et al. Expression of Neisseria meningitidis class 1 porin as a fusion protein in Escherichia coli: The influence of liposomes and adjuvants on the production of a bactericidal immune response. Microb Pathog 1996; 21:499–512.

    Article  PubMed  CAS  Google Scholar 

  68. Hoogerhout P, Donders EMLM, Van Gaans-van den Brink JAM. et al. Conjugates of synthetic cyclic peptides elicit bactericidal antibodies against a conformational epitope on a class 1 outer membrane protein of Neisseria meningitidis. Infect Immun 1995; 63:3473–8.

    PubMed  CAS  Google Scholar 

  69. Sardinas G, Gonzalez S, Garay HE et al. Anti-PorA antibodies elicited by immunization with peptides conjugated to P64k. Biochem Biophys Res Commun 2000; 277:51–4.

    Article  PubMed  CAS  Google Scholar 

  70. Peeters CCAM, Ciaassen IJTM, Schuller M et al. Immunogenicity of various presentation forms of PorA outer membrane protein of Neisseria meningitidis in mice. Vaccine 1999; 17:2702–12.

    Article  PubMed  CAS  Google Scholar 

  71. Peeters CCAM, Rümke HC, Sundermann LC et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996; 14:1009–15.

    Article  PubMed  CAS  Google Scholar 

  72. De Kleijn ED, De Groot R, Labadie J et al. Immunogenicity and safety of a hexavalent meningococcal outer-membrane-vesicle vaccine in children of 2–3 and 7–8 years of age. Vaccine 2000; 18:1456–66.

    Article  PubMed  Google Scholar 

  73. Cartwright K, Morris R, Rümke H et al. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins. Vaccine 1999; 17:2612–9.

    Article  PubMed  CAS  Google Scholar 

  74. De Kleijn ED, De Groot R, Lafeber AB et al. Immunogenicity and safety of monovalent P1.7h, 4 meningococcal outer membrane vesicle vaccine in toddlers: comparison of two vaccination schedules and two vaccine formulations. Vaccine 2000; 19:1141–8.

    Article  PubMed  Google Scholar 

  75. Martin SL, Borrow R, Van der Ley P et al. Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine. Vaccine 2000; 18:2476–81.

    Article  PubMed  CAS  Google Scholar 

  76. Jones DM, Borrow R, Fox AJ et al. The lipooligosaccharide immunotype as a virulence determinant in Neisseria meningitidis. Microb Pathog 1992; 13:219–24.

    Article  PubMed  CAS  Google Scholar 

  77. Zollinger WD, Moran EE, Devi SJN et al. Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines. Infect Immun 1997; 65:1053–60.

    PubMed  CAS  Google Scholar 

  78. Milagres LG, Brandileone MCC, Sacchi CT et al. Antibody studies in mice of outer membrane antigens for use in an improved meningococcal B and C vaccine. FEMS Immunol Med Microbiol 1996; 13:9–17.

    Article  PubMed  CAS  Google Scholar 

  79. Martin D, Cadieux N, Hamel J et al. Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exper Med 1997; 185:1173–83.

    Article  CAS  Google Scholar 

  80. Cadieux N, Plante M, Rioux CR et al. Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun 1999; 67:4955–9.

    PubMed  CAS  Google Scholar 

  81. Moe GR, Tan SQ, Granoff DM. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999; 67:5664–75.

    PubMed  CAS  Google Scholar 

  82. Delvig AA, Wedege E, Caugant DA et al. A linear B-cell epitope on the class 3 outer-membrane protein of Neisseria meningitidis recognized after vaccination with the Norwegian group B outer-membrane vesicle vaccine. Microbiology 1995; 141:1593–600.

    Article  PubMed  CAS  Google Scholar 

  83. Pon RA, Lussier M, Yang QL et al. N-propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neisseria meningitidis. J Exper Med 1997; 185:1929–38.

    Article  CAS  Google Scholar 

  84. Granoff DM, Bartoloni A, Ricci S et al. Bactericidal monoclonal antibodies that define unique meningococcal B polysaccharide epitopes that do not cross-react with human polysialic acid. J Immunol 1998; 160:5028–36.

    PubMed  CAS  Google Scholar 

  85. Pizza M, Scarlato V, Masignani V et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000; 287:1816–20.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Carl E. Frasch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret C. Bash
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Frasch, C.E., Bash, M.C. (2003). Neisseria meningitidis Vaccines. In: New Bacterial Vaccines. Medical Intelligence Unit. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-0053-7_15

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-0053-7_15

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4902-0

  • Online ISBN: 978-1-4615-0053-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation